Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Development, validation, and initial results of the angioedema activity score

Filename 170. Weller et al.,Dev.valid.and initial results of AAS,ALLERGY2013.pdf
Filesize 234.08 KB
Version o.170
Date added June 6, 2020
Downloaded 4 times
Category Original Work
Tags activity, angioedema, hereditary, urticaria, validation
Authors Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and Maurer, M.
Citation Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and Maurer, M.: Development, validation, and initial results of the angioedema activity score. Allergy 2013: 68; 1185-1192.
Corresponding authors Maurer, M.
DocNum O.170
DocType PDF
Edition; Page 68; 1185-1192
IF 5.99
Publisher Allergy
ReleaseDate 2013

Background: Recurrent angioedema (RecA) is a frequent clinical problem charac- terized by suddenly occurring cutaneous and/or mucosal swellings. Depending on their location, RecA may be painful, hindering, disfiguring, or even life-threaten- ing. The assessment of disease activity in affected patients is important to guide treatment decisions. Currently, however, there is no standardized and validated outcome measure available to do so.

Objective: To develop and validate the first specific patient-reported outcome instrument to assess disease activity in RecA patients, the Angioedema Activity Score (AAS).
Methods: After a set of potential AAS items was developed, item evaluation and reduction were performed by means of impact analysis, factor analysis, regression analysis, and by checking for face validity. In addition, the items of the final AAS questionnaire were tested for their validity and reliability during a 12-week validation study.

Results: In total, data from 110 and 80 RecA patients were used during the AAS item evaluation and validation phase, respectively. The resulting AAS consisted of five items and was found to have a one-dimensional structure and excellent internal consistency. It correlated well with other measures of disease activity and quality-of-life impairment, thus demonstrating its convergent validity. In addition, the known-groups validity and test–retest reliability of the AAS were found to be good.

Conclusions: The AAS is the first validated and reliable tool to determine disease activity in RecA patients, and it may serve as a valuable instrument in future clin- ical studies and routine patient care.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.